Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis

  • Technology appraisal guidance
  • TA320
  • Published: 
Download guidance (PDF)

7 Review of guidance

7.1 The guidance on this technology will be considered for review by the Guidance Executive when the review of NICE technology appraisal guidance 32, 127 and 254 has been published. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
August 2014